newsfilter
← Interviews
Bloomberg Television9 min

CVS Has Not Received Offers For the Retail Pharmacy Business, CEO Says

David Joyner

Interview
  • Strategic Decision & Rationale: CVS Health executives defended the impending spinoff of its retail pharmacy business (CVS Pharmacy) from a "position of strength," citing eight consecutive quarters of beating and raising guidance.
  • Market Performance: The retail pharmacy business, previously declining by negative 5%, is now on track for its third consecutive year of growth.
  • Corporate Structure Post-Spinoff:
    • Retained Entity (CVS Health): Will retain Aetna (insurer), Caremark (PBM), and specialty pharmacy assets, focusing on value-based care models and Medicare.
    • Standalone Entity (CVS Pharmacy): Will operate as a distinct company focused on non-specialty retail pharmacy, serving the 98% of customers who access standard medications.
  • Debt Allocation & Credit Quality:
    • Approximately $60 billion of total debt will be allocated between the two entities.
    • Management expects both resulting companies to maintain solid investment-grade credit ratings without leveraging up the retail business.
  • Strategic Rationale for Separation:
    • Specialty vs. General: The split separates the high-cost, specialized needs of the remaining 2% of patients (requiring different PBM capabilities) from the general retail model.
    • Pricing Model Shift: CVS transitioned from a cross-subsidization model to a cost-based reimbursement model to serve members profitably and rationalize pricing.
    • Competitive Strategy: Unlike competitors who filed for bankruptcy or went private under reimbursement pressure, CVS continued heavy investment in technology, consumer experience, and omni-channel delivery.
  • M&A and Valuation Status: No bidders have approached the company regarding the acquisition of retail assets; management expects the standalone entity to elevate the consumer brand and service capabilities.
  • Regulatory Context: CEO David Joyner stated the spinoff does not necessarily nullify regulatory pressures from politicians like Elizabeth Warren or Josh Hawley to break up healthcare conglomerates.
  • Leadership Outlook:
    • CEO David Joyner (40 years with the company) remains committed to the firm, citing a "say-do" ratio of delivering on promises.
    • Management plans to maintain focus for the next four to six quarters to execute the separation and ensure capital flexibility for both entities.